drugset / Trial / NCT00494871

Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

NCT00494871

Phase 3 Completed 1280 enrolled Bayer Janssen R&D, L.L.C. · collab
RandomizedParallel-groupTriple-blindPrevention

Summary

This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).

Timeline

Start
2007-06
Primary completion
2009-12
Completion
2010-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified 10 mg Oral
Subject Rivaroxaban Other / unclassified 15 mg Oral
Comparator Warfarin Small molecule Oral

Indications